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A novel peptide ADAM8 
inhibitor attenuates bronchial 
hyperresponsiveness and Th2 
cytokine mediated inflammation  
of murine asthmatic models
Jun Chen1,2, Linhong Deng1,2, Daniela Dreymüller3, Xuemei Jiang2, Jiaoyue Long2, 
Yiyuan Duan2, Yue Wang1, Mingzhi Luo1, Feng Lin2, Lizhen Mao4, Bernd Müller5, 
Garrit Koller6,7 & Jörg W. Bartsch7
A disintegrin and metalloproteinase 8 (ADAM8) has been identified as a signature gene associated 
with moderate and severe asthma. Studies in mice have demonstrated that the severity of asthma can 
be reduced by either transgenic knock-out or by antibodies blocking ADAM8 function, highlighting 
ADAM8 as potential drug target for asthma therapy. Here, we examined the therapeutic effect of an 
ADAM8 inhibitor peptide (BK-1361) that specifically blocks cellular ADAM8 activity in ovalbumin-
sensitized and challenged Balb/c mice. We found that BK-1361 (25 μg/g body weight) attenuated airway 
responsiveness to methacholine stimulation by up to 42%, concomitantly reduced tissue remodeling 
by 50%, and decreased inflammatory cells (e.g. eosinophils down by 54%)/inflammatory factors (e.g. 
sCD23 down by 50%)/TH2 cytokines (e.g. IL-5 down by 70%)/ADAM8-positive eosinophils (down by 
60%) in the lung. We further verified that BK-1361 specifically targets ADAM8 in vivo as the peptide 
caused significantly reduced levels of soluble CD23 in wild-type but not in ADAM8-deficient mice. These 
findings suggest that BK-1361 blocks ADAM8-dependent asthma effects in vivo by inhibiting infiltration 
of eosinophils and TH2 lymphocytes, thus leading to reduction of TH2-mediated inflammation, tissue 
remodeling and bronchial hyperresponsiveness. Taken together, pharmacological ADAM8 inhibition 
appears as promising novel therapeutic strategy for the treatment of asthma.
Asthma is a chronic pulmonary disease characterized by pathologic bronchial hyperresponsiveness (BHR), air-
way inflammation and airway tissue remodeling1–3. Whilst its aetiology is still unclear, asthma is treated with 
inhaled/oral bronchodilators and/or corticosteroids to mitigate the symptoms such as BHR and airway inflamma-
tion. However, these therapeutic strategies are not only limited in efficacy beyond the provision of symptomatic 
relief, but also known for undesirable side effects, particularly with long-term use of steroids, as well as a high 
incidence of drug-resistance4. Therefore, there is a pressing need to develop new therapies that may overcome the 
shortcomings of the currently available treatment modalities.
One potential alternative therapeutic approach is to target asthma-associated proteins as suggested by the 
DNA microarray analysis for whole-lung RNA of allergen-challenged mice5. From this perspective, a disinte-
grin and metalloprotease 8 (ADAM8) is of particular interest since it has been identified as a signature gene 
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associated with moderate to severe asthma. In sputum and endobronchial biopsies obtained from moderate and 
severe asthmatic patients, and in lungs of experimental murine asthma model, ADAM8 is more abundant. The 
increase in ADAM8 expression occurs in bronchial epithelium, perivascular and peribronchial immune cells 
such as eosinophils, macrophages, monocytes, dendritic cells (DCs) and B lymphocytes6–14. Moreover, it has 
been shown that for full manifestation of asthma, ADAM8 is required to be expressed in both hematopoietic 
and non-hematopoietic cells, however, loss of ADAM8 on T cells alone is sufficient to decrease asthma response 
significantly11, demonstrating an important role of ADAM8 in asthma pathogenesis. Furthermore, ADAM8 is 
known to be highly inducible by inflammatory stimuli such as interferon (IFN)-γ, lipopolysaccharide (LPS) and 
tumor necrosis factor (TNF)-α, suggesting a regulatory role in inflammation15,16. Moreover, there is evidence that 
ADAM8 can act as a sheddase for various cytokines and molecules involved in cell adhesion and extra cellular 
matrix (ECM) attachment such as CD23, L-selectin, vascular cell adhesion molecule-1 (VCAM-1), neural cell 
adhesion molecule close homologue of L1 (CHL1), pro-TNF and fibronectin. Thus, activities of ADAM8 causing 
the release of inflammatory cytokines, adhesion molecules and degradation of ECM proteins, are all instrumen-
tal for immune cell recruitment and the subsequent immune response in asthma17–22. More importantly, loss 
of ADAM8 in ADAM8-knockout mice, whilst showing no effect on the fertility and development of the mice, 
provides moderate protection from BHR and airway inflammation in ovalbumin (OVA)-induced experimental 
murine model of asthma, suggesting that transient and specific inhibition of ADAM8 function in vivo might be a 
potential method for treating asthma without major side effects11,23.
Thus, the pathological induction of ADAM8 under inflammatory conditions on the one hand and its dis-
pensability for homoeostasis on the other hand favors ADAM8 as a promising therapeutic target. To test this 
hypothesis, the current study examined the therapeutic effect of a specific peptide inhibitor of ADAM8, named 
BK-1361, on an established, OVA-induced murine model of asthma. This peptide has recently been demon-
strated to specifically inhibit autocatalytic activation and cellular shedding ability of ADAM8 through blocking 
the disintegrin/cysteine rich domain-mediated ADAM8 multimerisation without interfering with the catalytic 
activities of other proteases including ADAM9, 10, 12, 17, and matrix metalloproteinase (MMP)-2, -9 and -14, 
respectively24. Furthermore, the administration of BK-1361 peptide at 1, 5, 10 μg/g body weight (abbreviated as 
μg for the unit of dosage, thereafter) either in a single or repeated doses causes no toxic effect in mice as no abnor-
malities at histological level are observed, but the inhibition of ADAM8 by BK-1361 in a pancreatic ductal ade-
nocarcinoma (PDAC) mouse model causes a significant therapeutic effect by reducing the grade of cell migration 
and infiltration, and thus reduced metastasis24. These findings prompted us to evaluate the potential of BK-1361 
as an alternative therapeutic agent in asthma. We found that treatment with BK-1361 could effectively attenuate 
BHR, bronchial inflammation and airway wall tissue remodeling in OVA-sensitized and challenged Balb/c mice, 
by specifically targeting ADAM8 and thus suppressing the expression of important TH2 cytokines in vivo. These 
findings, therefore, provide the first evidence that targeting ADAM8 with a specific inhibitor such as BK-1361 
may have great potential as a novel therapy for asthma treatment, and warrants further evaluation.
Results
ADAM8 inhibition with BK-1361 reduces the extent of airway responsiveness. Methacholine 
(MCh) challenge caused dose-dependent increase of enhanced pause (Penh) measured by plethysmography in 
all cases, but the extent to which Penh increased in response to same dose of MCh stimulation was variable in the 
different treatment groups (Fig. 1). In the absence of BK-1361, OVA-sensitized and challenged mice displayed 
significantly higher Penh, indicating BHR compared to non-sensitized mice (OVA vs. control, p < 0.05). However, 
the OVA-sensitized & challenged mice treated with a dose of 25 μg BK-1361 had only a moderate response to 
MCh compared to their counterparts without BK-1361 treatment (Penh = 4.24 ± 0.06 in 25 μg vs. 7.28 ± 0.15 
in OVA at 50 mg/mL MCh, p < 0.05), indicating desirable control of BHR by BK-1361. The effect of BK-1361 at 
10 μg dosage was similar, but not as evident as that at 25 μg (Penh = 5.43 ± 0.08 in 10 μg vs. 7.28 ± 0.15 in OVA at 
50 mg/mL MCh, p < 0.05).
BK-1361 reduces bronchial tissue remodeling. Next, we assessed the effect of BK-1361 on bronchial 
tissue remodeling (Fig. 2). Representative histological lung sections stained with either hematoxylin & eosin 
(H&E) or Pikosirius-Red for each group are shown in Fig. 2a–f, respectively, and their quantitative scores for 
extent of tissue remodeling are summarized in Fig. 2g. Compared to the control group (Fig. 2a,d), sensitization 
and challenge with OVA induced significant tissue inflammation and remodeling in the mouse bronchial airways, 
characterized by severe perivascular (PV), peribronchial (PB), and parenchymal (PA) infiltration of inflamma-
tory cells together with bronchial epithelial damage (ED) (Fig. 2b vs. a). Furthermore, the group exhibited severe 
hyperplasia of collagen and fibrin in the bronchiolar basement membrane (Fig. 2e vs. d). This resulted in an over-
all high total histological score of 15.40 ± 1.47 for this group as compared to 5.40 ± 0.75 for the non-sensitized 
mice (OVA vs. control, p < 0.05 in Fig. 2g). OVA-sensitized & challenged mice treated with BK-1361 at 25 μg had 
less severe PV and PB (Fig. 2c vs. b), and displayed a reduced hyperplasia of the basement membrane and an 
almost complete absence of ED (Fig. 2f vs. e), resulting in a decreased histological score of 8.20 ± 0.97 as com-
pared to that for the OVA group (25 μg vs. OVA, p < 0.005 in Fig. 2g). However, the treatment of BK-1361 at 10 μg 
showed little effect on tissue remodeling (10 μg vs. OVA in Fig. 2g, lung section images not shown).
BK-1361 reduces bronchial inflammation. The total cell counts and differential cell counts of inflam-
matory cells in bronchoalveolar lavage fluid (BALF) were quantified to evaluate the therapeutic effect of BK-1361 
on the invasion of inflammatory cells into airways. As shown in Fig. 2h, the OVA-sensitized & challenged mice 
exhibited approximately 50% higher total cell counts in BALF as compared to their non-sensitized counterparts 
(OVA vs. control, p < 0.05), indicating increased infiltration of inflammatory cells in the murine asthma model, 
as mirrored by the human clinical presentation. However, significant decreases in cell number in BALF were 
www.nature.com/scientificreports/
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observed after administration of BK-1361 at both 10 μg and 25 μg to OVA-sensitized & challenged mice (10 μg 
and 25 μg vs. OVA, p < 0.05), suggesting that treatment with BK-1361 reduced the invasion of inflammatory cells 
into the airways.
For differential cell counts, OVA-sensitized & challenged mice showed a dramatically increased proportion of 
eosinophils in BALF when compared to the non-sensitized mice (OVA vs. control, p < 0.005), as shown in Fig. 2i 
and observed in previous studies6,25,26. This increase of eosinophils proportion, however, was significantly reduced 
by administration of BK-1361 at 25 μg (25 μg vs. OVA, p < 0.005), suggesting an inhibition of prominently eosino-
philic infiltration in airways due to BK-1361. Interestingly, as shown in Table 1, it appeared that the proportion of 
neutrophils or lymphocytes in BALF was not affected by OVA-sensitization and BK-1361 treatment. In contrast, 
the proportion of macrophages in BALF was reduced in OVA-sensitized & challenged mice, but then increased 
when the mice were subsequently treated with BK-1361, even though the absolute number of macrophages in 
BALF was lowered by BK-1361 treatment (data not shown).
BK-1361 reduces the recruitment of ADAM8-positive eosinophils. To understand the in situ effects 
of BK-1361 on the expression and distribution of ADAM8 further, we examined mouse lung sections for the pres-
ence of ADAM8-positive eosinophils using immunohistochemistry (IHC) since eosinophils are known to express 
ADAM8 protein24. As shown in Fig. 3, we found that in lung sections from OVA-sensitized & challenged mice, 
when compared to their non-sensitized counterparts, there were not only more eosinophils and bronchial epi-
thelial cells, as well as increased interstitial edema (Fig. 3b/e vs. a/d), but also more detectable ADAM8-positive 
eosinophils (Fig. 3e/h vs. d/g). In contrast, when the OVA-sensitized mice were treated with BK-1361 at 25 μg 
dosage, not only the fibrosis thickening of bronchiolar epithelium was reduced, but also the number of detectable 
ADAM8-positive eosinophils in the lung sections (Fig. 3c/f/i vs. b/e/h). The quantitative estimates of bronchi-
ole wall thickness and the number of ADAM-positive eosinophils observed in the above are summarized in 
Fig. 3j and k respectively. All these results suggest that inhibition of ADAM8 by BK-1361 reduces migration of 
ADAM8-positive cells into the airways.
BK-1361 reduces mRNA expression of key TH2 cytokines. Asthma is also thought to be induced by 
TH2 cytokines, and we thus explored the mechanism underlying the therapeutic effect of BK-1361 by assess-
ing the quantitative mRNA expression of several key TH2 cytokines associated with pathogenesis of asthma, 
including interleukins (IL)-4, IL-5, IL-13, chemokine (C-C motif) ligand (CCL)5, CCL11 and CCL22. In agree-
ment with previous observations6,11, the mRNA expression of all these cytokines in lungs of OVA-sensitized & 
challenged mice were significantly increased compared to non-sensitized mice (p < 0.05), and reduced in the 
BK-1361 treated group (Fig. 4a–f). More specifically, treatment with BK-1361 at 25 μg resulted in significant 
decrease in expression of IL-5, IL-13 and CCL5, CCL11 and CCL22 compared to OVA-sensitized & challenged 
mice (p < 0.05). Remarkably, treatment with BK-1361 of OVA-sensitized & challenged mice appeared to reduce 
the expression of CCL5, CCL11 and CCL22 to even below that of non-sensitized mice. Treatment with BK-1361 
at 10 μg reduced the expression of IL-4, IL-5, CCL5 and CCL11 in similar fashion to that at 25 μg. The decreased 
expression of TH2 cytokines was also correlated with the decreased infiltration of inflammatory cells as described 
above, suggesting a beneficial effect of BK-1361 on TH2 cytokine-mediated airway inflammation.
Figure 1. Airway resistance (Penh) of Balb/c mice versus methacholine (MCh) concentration. Penh was 
measured by using whole-body plethysmography when mice were stimulated with MCh at increasing doses. 
In all cases, Penh increased with increasing MCh. However, Penh of mice (OVA, open circles), as compared to 
non-sensitized mice (Control, solid circles) increased to a much greater extent in response to increasing dose of 
MCh stimulation, indicating bronchial hyperresponsivess (BHR). This large response of Penh to MCh in OVA-
sensitized and challenged mice was attenuated dose dependently by treatment with BK-1361 (OVA, open circles 
versus 10 μg, solid triangles, and 25 μg, open triangles, respectively). There are statistical significances between 
OVA and Control, OVA and 25 μg, Control and 10 μg, Control and 25 μg, 10 μg and 25 μg (P < 0.05). Data are 
representative of two independent experiments with n = 8–10 age-matched female mice for each group. Results 
are expressed as mean ± SEM. *P < 0.05 versus control. #P < 0.05 versus OVA.
www.nature.com/scientificreports/
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BK-1361 reduces the levels of soluble CD23 and ADAM8 in lungs of OVA-sensitized & chal-
lenged mice. CD23, the low affinity immunoglobin E (IgE) receptor, has been identified as a substrate 
of ADAM8 in vitro21. Previously, we have demonstrated that BK-1361 inhibits shedding of mouse CD23 in a 
Figure 2. Representative micrograph images of lung sections and the quantitative histological scores, 
as well as total cell number and eosinophil percentage in BALF. Lung tissue sections were stained by 
hematoxylin & eosin (H&E) and Pikosirius-Red as shown in panel a–c, and panel d–f, respectively. Panel a 
and d, b and e, c and f correspond to lung sections from control, OVA and OVA/BK-1361 (25 μg/g bodyweight) 
groups, respectively. The bar in panel a–c equals 50 μm, whereas the bar in panel d-f equals 25 μm. The arrows 
in panel a–c point to perivascular infiltration (PV), peribronchial infiltration (PB), parenchymal infiltration 
(PA), epithelial damage (ED), respectively. The arrows in panel d–f point to collagen and fibrin deposition in 
the bronchiole basement membranes. Panel g displays the quantified histological scores considering the extent 
of PV, PB, PA and ED in the lung tissue sections from different groups of mice, with score 0 indicating no sign 
of disease, score 5 indicating profound inflammation for each index, thus 20 being the maximum. Panels h and 
i display the total cell counts number and the percentage of eosinophils in bronchoalveolar lavage fluid (BALF) 
from different groups of mice respectively. Data in panel g are representative of two independent experiments 
with n = 7–9 age-matched female mice for each group, and data in panel h and i are representative of n = 5–6 
female mice per group. Results are expressed as mean ± SEM. *P < 0.05, **P < 0.005 versus control. #P < 0.05, 
##P < 0.005 versus OVA.
% control OVA 10 μg 25 μg
Eosinophils 5.25 ± 0.59 41.75 ± 2.55 ** 35.00 ± 3.55 ** 19.00 ± 2.30 *, ##
Neutrophils 9.50 ± 1.21 12.25 ± 1.65 11.08 ± 1.19 10.08 ± 1.25
Lymphocytes 15.75 ± 2.47 20.83 ± 1.30 19.42 ± 1.00 13.83 ± 0.77 #
Macrophages 69.50 ± 4.03 25.17 ± 1.99 ** 34.50 ± 2.35 ** 57.08 ± 3.66 ##
Table 1.  Percentage of inflammatory cells in BALF from different groups of Balb/c mice. Differential 
cell counts of four major types of inflammatory cells including eosinophil, neutrophil, lymphocyte and 
macrophage were obtained, and percentages of each cell type from total cell numbers was calculated for control 
group (control), OVA-sensitized and challenged group (OVA), and group of OVA-sensitization with BK-1361 
treatment at either dose of 10 μg (10 μg) or 25 μg (25 μg) respectively. Data are representative of two independent 
experiments with n = 5–6 age-matched female mice for each. Results are expressed as mean ± SEM. *P < 0.05,  
**P < 0.005 versus control. #P < 0.05, ##P < 0.005 versus OVA.
www.nature.com/scientificreports/
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cell-based shedding assay24. Here, we further investigated whether in vivo BK-1361 could either affect the shed-
ding of CD23 through inhibiting the catalytic activity and endogenous processing of ADAM8, or reduce the 
CD23 and ADAM8 expression through decreasing the overall inflammation by assessing the expression of both 
soluble CD23 (sCD23, produced by CD23 shedding) and soluble ADAM8 (sADAM8, produced by endogenous 
processing of ADAM8) in lungs. The concentrations of sCD23 and sADAM8 were determined by ELISA in cen-
trifuged supernatants of homogenized lung extracts. As shown in Fig. 5, when mice were OVA-sensitized and 
challenged, the concentrations of sCD23 and sADAM8 were both increased (OVA vs. control, p < 0.05, in both 
Fig. 5a,b), which is in agreement with previous findings6,12. However, when OVA-sensitized & challenged mice 
were treated with BK-1361, the concentration of sCD23 was significantly decreased (OVA vs. either 10 μg or 
25 μg, p < 0.05, in Fig. 5a), whilst that of sADAM8 remained similar (OVA vs. either 10 μg or 25 μg, p > 0.05, in 
Fig. 5b), indicating that the inhibition of ADAM8 by BK-1361 in vivo resulted in reduced shedding of CD23.
Figure 3. Expression of ADAM8 in lung tissue sections from different groups of Balb/c mice. Lung tissue 
sections were stained by hematoxylin & eosin (H&E) shown in panel a–c, and immunohistochemistry (IHC) 
shown in panel d–f to visualize bronchiolar structure and ADAM8 expression, respectively. Panel g-i display 
zoom-in images corresponding to panel d–f, with arrows pointing to ADAM8-positive eosinophils. The bar in 
panel a-f equals 25 μm, whereas the bar in panel g-i equals 12.5 μm. The left, middle, and right column of images 
represents lung tissue sections from control group (panel a, d, g), OVA group (panel b, e, h), and OVA/BK-
1361 group (panel c, f, i), respectively. Note the OVA-induced thickening of bronchiolar epithelium compared 
to control (panel b vs. a), which was reduced by BK-1361 treatment (panel c vs. b), and the OVA-induced 
fibrotic changes (panel h vs. g), which was also reduced by BK-1361 treatment (panel i vs. h). ADAM8-positive 
eosinophils (ADAM8+ cells) appeared mainly in OVA group (panel h vs. g), and became much less abundant 
after BK-1361 treatment (panel i vs. h). Panel j, k displays quantified bronchial wall thickness, and number of 
ADAM8+ cells, respectively. Data are representative of two independent experiments with n = 30–40 counts 
from 3–4 age-matched female mice per group. Result are expressed as mean ± SD. **P < 0.005 versus control. 
##P < 0.005 versus OVA.
www.nature.com/scientificreports/
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BK-1361 reduces CD23 shedding in wild-type but not in ADAM8-deficient mice. To further ver-
ify that the decreased sCD23 expression was due to a dampened CD23 cleavage in vivo provided by the spe-
cific inhibitory effect of BK-1361 on ADAM8, we administered BK-1361 in ADAM8-deficient and wild-type 
mice at a dosage of 10 μg intraperitoneally (i.p.) daily for one week, respectively, and examined the total CD23 
in lung tissues lysates and sCD23 in the soluble protein fraction by ELISA, whilst the sCD23 protein levels in 
lysates were also examined by western blot. As shown in Fig. 6a, there is not significant difference in the con-
centrations of total CD23 in the lysates from wild-type mice with or without treatment of BK-1361. In addition, 
ADAM8-deficient mice showed only a mild decrease in total CD23 concentrations as compare to wild-type mice, 
and treatment with BK-1361 did not result in further decrease (Fig. 6a). These data suggest that the total CD23 
expression is independent of ADAM8 activity in vivo. However, the sCD23 level in both the soluble protein 
Figure 4. mRNA expression of TH2 cytokines in total lung tissue from different groups of Balb/c mice. The 
level of mRNA expression was quantified by RT-PCR with detection of β-actin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as endogenous controls. Panel a–f display the normalized fold expression of IL-4, 
IL-5, IL-13, CCL5, CCL11, and CCL22, respectively, for mice of control group (control), OVA-sensitized and 
challenged group (OVA), and group of OVA-sensitization with BK-1361 treatment at either dose of 10 μg (10 μg) 
or 25 μg (25 μg). Data are representative of two independent experiments with n = 3–4 age-matched female mice 
per group. Result are expressed as mean ± SEM. *P < 0.05, **P < 0.005 versus control. #P < 0.05, ##P < 0.005 
versus OVA.
www.nature.com/scientificreports/
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fractions (Fig. 6b) and the lung tissue lysates (summarized in Fig. 6c, specific band of ~38 kDa as shown in 
Fig. 6d) appeared to be reduced considerably in the ADAM8-deficient mice compared to the wild-type mice. 
Figure 5. Concentration of soluble CD23 (sCD23) and soluble ADAM8 (sADAM8) in soluble protein 
fraction from different groups of Balb/c mice. The concentration of sCD23 and sADAM8 was quantified by 
ELISA, and is displayed in Panel a and b respectively, for mice of control group (control), OVA-sensitized and 
challenged group (OVA), and group of OVA-sensitization with BK-1361 treatment at either dose of 10 μg (10 μg) 
or 25 μg (25 μg). Each experiment was performed in duplicate or triplicate with n = 5–6 samples per group. 
Result are expressed as mean ± SEM, *P < 0.05.
Figure 6. ELISA and Western Blot (WB) analysis of CD23 in wild-type (“litter”) and ADAM8-deficient 
(“KO”) mice after treatment with either saline or BK-1361 at 10 μg via intraperitoneal injection (i.p.) daily 
for 7 days. Total CD23 in lung tissue lysates and soluble CD23 (sCD23) in soluble protein fraction detected via 
ELISA are presented in panel a, and b respectively. The WB analysis results of sCD23 in lung tissue lysates and 
the representative image ofWB bands of CD23 are displayed in panel c, and d, respectively. Note the band for 
sCD23 around 38 kDa. For the quantification, values are derived from n = 3 (wild-type) and n = 4 (ADAM8-
deficient) and are given as mean ± SEM. *p < 0.05 versus litter treated with saline.
www.nature.com/scientificreports/
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Furthermore, the application of BK-1361 for one week resulted in significantly reduced sCD23 levels in both 
soluble protein fractions (Fig. 6b) and the lung tissue lysates (Fig. 6c) from the wild-type mice compared to the 
control group that received saline only (litter + BK-1361 vs. litter + saline, p < 0.05, in Fig. 6b/c). By contrast, the 
treatment of BK-1361 for one week failed to cause further decrease of the sCD23 levels either in the soluble pro-
tein fractions or lung tissue lysates (Fig. 6b/c) from ADAM8-deficient mice. These data suggest that ADAM8 is 
involved in shedding of CD23 in vivo, and more importantly, BK-1361 reduces shedding of CD23 in vivo through 
inhibition of ADAM8.
Discussion
In this study, we assessed the potential therapeutic effect of BK-1361, a specific peptide inhibitor of ADAM8, 
in treatment of the OVA-induced murine model of asthma. For this purpose, BK-1361 was administered to 
OVA-sensitized and challenged Balb/c mice at a dose of 10 μg or 25 μg during sensitization. These doses were 
predetermined according to preliminary experiments as described in the Methods.
We found that treatment with BK-1361 at 25 μg significantly reduced the extent of MCh-induced increase 
in Penh in OVA-sensitized & challenged mice, whilst at 10 μg the reduction was only moderate (Fig. 1). This 
result indicates an attenuated BHR in OVA-sensitized & challenged mice when ADAM8 activity was blocked 
by BK-1361, which is in agreement with previous observations in ADAM8-deficient mice11,25. To elucidate the 
mechanism underlying the attenuated BHR mediated by BK-1361, we further assessed the severity of airway 
inflammation and airway remodeling in OVA-sensitized & challenged mice after treatment of BK-1361.
The total cell number count (Fig. 2h), the percentage of eosinophils in BALF (Fig. 2i and Table 1), the severity 
of PV, PB, ED and hyperplasia in airway smooth muscle (ASM) layer and basement membrane, fibrosis in lung 
tissue and thickening of bronchiolar epithelium (Fig. 2c,f, also see Figure S7) were all decreased after administra-
tion of BK-1361 at the 25 μg dose, suggesting that the severity of eosinophilic inflammation and tissue remodeling 
in airways were reduced when ADAM8 activity was inhibited by BK-1361. This is in agreement with previous 
observations with ADAM8 either being knocked out or inhibited by antibody treatment in murine models11,25. 
This attenuated asthma response is likely to stem from the impaired recruitment of inflammatory cells, such as 
eosinophils, into the airways.
As reported before, it is essential in the elicitation and development of an asthma response that inflammatory 
cells migrate from the surrounding vasculature into airway mucosa and bronchoalveolar space27–29. This leads to 
exaggerated recruitment of these cells to bronchial and perivascular sites, which aggravates airway inflammation 
and subsequently contributes to the remodeling process of airway structures including functional alterations 
of epithelial cells, fibroblasts and ASM cells, ultimately leading to enhanced BHR and airway constriction30–32. 
Previous studies have also demonstrated a functional association of ADAM8 in the migration of various inflam-
matory cells and ECM degradation, indicating an important regulatory role of ADAM8 in the infiltration and 
recruitment of these cells to sites of airway inflammation11,17,22,33,34. Therefore, ADAM8 inhibition by BK-1361 
provides a promising opportunity for the treatment of asthma.
In agreement with this notion, our results seem to imply that BK-1361 may treat asthma through a mechanism 
of directly inhibiting ADAM8 activity on inflammatory cells, especially eosinophils, and thus reducing their 
ability to migrate into the bronchoalveolar space, consistent with its role in reducing cellular invasion in a PDAC 
mouse model24.
To further support this proposed mechanism underlying the therapeutic effect of BK-1361, we detected 
mRNA expression of several typical TH2 cytokines including IL-4, -5, -13 and CCL5, 11, 22 in lung tissues of mice. 
These cytokines are known to activate inflammatory and residential effector pathways in asthma both directly and 
indirectly35–37. Specifically, both IL-4 and IL-13 regulate differentiation of TH0 cells to develop a TH2 phenotype 
and stimulate B cells to produce IgE. IL-5 promotes proliferation of eosinophils, which together with IgE are both 
important components in development of allergic inflammation and BHR1,38. CCL22 is a macrophage-derived 
chemokine and plays an important role in chronic allergic inflammation39. CCL11 is mainly secreted by eosin-
ophils40,41, and CCL5 is thought to be involved in pathogenesis of late-onset asthma42. Accordingly, the expres-
sion levels of these typical TH2 cytokines could offer an overall reflection of severity of TH2 cytokines-mediated 
inflammation. Interestingly, ADAM8 has been reported as an IL-4 and IL-13 induced gene and can be regulated 
through different signaling pathway in experimental asthma6,26. In addition, decreased expression of CCL11 and 
CCL22 in OVA-sensitized & challenged mice with Adam8 knockout or knocked down have also been demon-
strated before25, indicating that ADAM8 is involved in the TH2 cytokines-mediated inflammation. In agreement 
with this view, our results showed significantly decreased expression levels of IL-5, CCL5, CCL11 and CCL22, 
and moderately attenuated expression of IL-4 and IL-13 in OVA-sensitized & challenged mice that were treated 
with BK-1361 at either 10 μg or 25 μg as compared to their untreated counterparts (Fig. 4). These results suggest a 
desirable control of TH2 cytokines-mediated inflammation in OVA-sensitized & challenged mice by inhibition of 
ADAM8 function in vivo, which may also be induced by the impaired recruitment of TH2 cells
In addition, ADAM8 has been shown in vitro to shed CD23 that binds to IgE and eventually results in immune 
response43. Expression of CD23 is decreased in IL-4- and IL-13-deficient mice, indicating a synergistic mode 
between CD23 and IL-4/IL-1338. In agreement with these observations, our results showed decreased sCD23 
level in the soluble protein fractions from lung tissues of OVA-sensitized & challenged mice after treatment with 
BK-1361 at either 10 μg or 25 μg (Fig. 5a), associated with a decreased mRNA expression of IL-4 and IL-13 as 
described above. This decreased sCD23 level might be a combinatorial result of an overall decreased inflamma-
tory cells invasion mediated by BK-1361, as well as BK-1361-dependent inhibition of catalytic ability of ADAM8 
to cleave CD23 in vivo. However, BK-1361 appeared to have little effect on the concentration of sADAM8 
(Fig. 5b), which may also be reasonable considering that BK-1361 inhibits substrate shedding but not the expres-
sion of ADAM8 in vivo.
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Furthermore, BK-1361 is known to specifically target ADAM8 in vitro as observed in an ADAM8-dependent 
cell migration assay24. As shown in Fig. 6b/c, BK-1361 significantly reduced the sCD23 level in the presence of 
ADAM8 in wild-type mice, however, when ADAM8 was lacking in ADAM8-deficient mice, the treatment of 
BK-1361 either had little effect on the sCD23 level in the soluble protein fraction (Fig. 6b, detected by ELISA), 
or resulted in a only mild decrease in sCD23 levels in lung tissue lysates (Fig. 6c, detected by western blot). This 
suggests that BK-1361 also targets ADAM8 in vivo to at least in part reduce the shedding of sCD23 according to 
the latter’s dependence on the presence of ADAM8. Although ADAM8 is not the only ADAM protease that serves 
as a sheddase for CD23 in vitro, and it is even controversial whether ADAM8 sheds CD23 in vivo44, the observed 
decrease in CD23 shedding in wild-type mice could only result from the effect of BK-1361 on ADAM8 but not 
on other ADAM proteases such as ADAM10 as described before24. However, it is still possible that inhibition of 
CD23 shedding can be either direct or indirect (i.e. by inhibiting activation of ADAM10 mediated by ADAM8). 
Interestingly, the ADAM8-deficient mice showed no difference on total CD23 expression levels but decreased 
sCD23 levels compared to wild-type mice, indicating that ADAM8 might at least account for partial CD23 shed-
ding in vivo.
It is worth noting that although several studies have assessed the role of ADAM8 in experimental asthma, 
the findings of these studies seem to be controversial11,25,45,46. This may have been caused, at least partially, by 
the different mouse strains used in those studies. For example, the TH1-skewed strains (such as C57Bl/6 strain) 
have congenitally reduced recruitment of eosinophils and TH2 cells during airway inflammation compared to 
TH2-skewed strains3,47. Here we show that in a pure TH2-skewed strain (Balb/c strain), ADAM8 facilitated the 
infiltration of eosinophils and TH2 cells and thus participated in the aggravation of asthma airway inflammation.
There are recognized limitations of the current study. For instance, we evaluated the therapeutic effect of 
BK1361 only in an acute murine model of asthma, which is more relevant to inflammatory mechanisms of the 
disease. For the long-term effect of BK-1361 on asthma, and particularly on tissue remodeling as a consequence of 
prolonged inflammation48, chronic murine asthma models are required in future studies. In addition, the half-life 
of current form of the peptide is relatively short24, which should be extended in order to further assess its efficacy 
and therapeutic dosing strategy, as well as possible clinical use. Another issue is that in the present study, Penh, 
an unrestrained plethysmography parameter, was used as an indicator of BHR in mice. This technique is advan-
tageous in terms of convenience and non-invasiveness. However, it has been questioned whether measurement 
of Penh truly reflects the BHR as compared to the measurement of changes of airway resistance by direct tech-
nique such as force oscillatory technique (FOT)49,50. Although Penh is not considered the best choice for accurate 
measurement of BHR in general, this technique may still be used to estimate BHR under specific, controlled 
conditions. For example, it has been shown that Penh is well correlated with airway resistance only when Balb/c 
mice are stimulated with MCh at high dose so that the variations of nonmechanical origins are minimized49. 
Considering that we also used Balb/c mice and the highest dosage of MCh (50 mg/mL) in this study, as well as a 
well-established protocol to induce BHR, it is probably reasonable that the measured Penh largely reflected the 
airway resistance and thus was justified to quantitatively characterize BHR.
Taken together, our findings demonstrate that ADAM8 might be a novel drug target for treatment of allergic 
asthma, perhaps other TH2 cytokines-mediated inflammatory diseases as well, because inhibition of ADAM8, at 
least with BK-1361, could suppress asthma symptoms from BHR to airway inflammation and tissue remodeling 
without major side-effects in this model used.
Materials and Methods
Chemicals and reagents. OVA (grade V) was purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA); aluminum hydroxide was purchased from Kelong Tech. Co. (Chengdu, China); methacholine was pur-
chased from Tokyo Chemical Industry Co. (Tokyo, Japan); hematoxylin & eosin stain, Wright–Giemsa stain 
was purchased from Jiancheng Tech. Co. (Nanjing, China); TRIzol solution was purchased from Bioteke Co. 
(Beijing, China); RevertAid First Strand cDNA Synthesis Kit was purchased from Thermo Fisher Scientific Inc. 
(Waltham, MA, USA); Oligonucleotide primers were produced by Invitrogen Life Technologies Co. (Shanghai, 
China); SsoFast EvaGreen Supermix was purchased from Bio-Rad Laboratories (Hercules, CA, USA); ELISA 
kits for soluble CD23 (sCD23) and soluble ADAM8 (sADAM8) was purchased from either Life Science Inc. 
(Wuhan, China)or R&D Systems (Wiesbaden, Germany); NanoDrop was purchased from PeqLab (Erlangen, 
Germany); the ADAM8 antibody (Cat#: orb4376) was purchased from Biorbyt (Cambridge, U.K.), CD23 anti-
body (abb185807) from Abcam (Cambridge, U.K.), goat anti-mouse HRP and goat anti-rabbit HRP from Jackson 
ImmunoResearch (West Grove, PA, USA), mouse anti-GAPDH from Thermo Fisher Scientific (Waltham, MA, 
USA); VECTASTAIN Elite ABC Kit was purchased from Vector Laboratories (Peterborough, U.K.).
Experimental animals. Balb/c mice were purchased from the Laboratory Animal Centre of Third 
Military Medical University (Chongqing, China), maintained and bred in specific pathogen-free environment. 
ADAM8-deficient (Adam8−/−) and their wild-type littermates (Adam8+/+) mice were kept under SPF conditions 
in the mouse facility (Marburg University, Germany). Peptide injection experiments were performed with permit 
by the local authorities (Regierungspräsidium Giessen). All other animal experiments in this study were approved 
by the Institutional Animal Care and Research Advisory Committee of Third Military Medical University and 
performed in accordance with the guidelines of the Chinese Council on Animal Care (Approved No. 11172340, 
LHD).
Allergen sensitization. Three to four weeks old Balb/c mice were randomly divided into four groups: 
OVA-sensitized and challenged group (abbreviated as OVA), OVA-sensitized and challenged with BK-1361 
treatment group (abbreviated as OVA/BK-1361) and Control group (abbreviated as control), n = 8–10 for each 
group. Mice in both OVA and OVA/BK-1361 were sensitized with OVA following standard procedures of previous 
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studies2,11 (please see Figure S1 in the supplements for detailed protocol). Specifically, for OVA and OVA/BK-1361 
group, 3–4 weeks old Balb/c mice were first acclimatized for 3 weeks, and then injected i.p. with 10 μg OVA and 
100 μg aluminum hydroxide suspended in 1 mL sterile isotonic saline once a week for 3 weeks. Subsequently, 
the mice were exposed to aerosolized challenge of sterile isotonic saline comprising 1% OVA (1% w/v in sterile 
isotonic saline) for 30 min once every day for a week. Mice in the control group were treated with sterile saline 
using the same protocol.
Design and administration of a peptide inhibitor specific for ADAM8 (BK-1361). BK-1361 was 
described previously and has been tested for safety and efficacy in mice elsewhere24. In brief, homology mode-
ling was performed based on the X-ray structure of the ADAM10 disintegrin domain51. An exposed sequence 
within the putative integrin binding loop was targeted by creating cyclic peptide variants that match the exposed 
sequence KDK in mouse ADAM8. Thus the optimal cyclic peptide was shown to be cyclo “RLsKDK” with “s” 
being a D-serine residue. The BK-1361 was synthesized by Peptide 2.0 (Chantilly, VA, USA) with a purity of 
>97%, and then dissolved in phosphate buffered saline (PBS) at a stock concentration of 1 mg/mL, prior to fur-
ther dilutions.
Our previous study has showed that the serum concentrations of BK-1361 in mice after injecting 10 μg/g 
bodyweight BK-1361 via an i.p. route reached as high as ~37 ng/μL with a half life of ~34 min, indicating a good 
distribution of BK-1361 in the body of mice. In addition, administration of 1, 5, 10 μg/g body weight of BK-1361 
either in single or repeated doses for up to 4 weeks has been suggested to have no acute or chronic toxicity effect 
to mice as no abnormalities at histological levels was observed24. Similarly, in our preliminary experiment, the 
mice with administration of 10, 25, 33 and 50 μg/g body weight of BK-1361 for up to 1 week showed no signs of 
weight loss, abnormal behavior or abnormal motor performance over study period, suggesting BK-1361 was well 
tolerated in Balb/c mice. Among the dosages we used, no further improvement beyond 25 μg observed (such as 33 
and 50 μg/g body weight, please see Figures S2–6 in the supplements). Accordingly, for the OVA/BK-1361 group, 
the peptide was administered in mice with a dose of either 10 μg/g or 25 μg/g body weight of mouse (abbreviated 
as 10 μg and 25 μg respectively). The body weight of each mouse, which varied between ~19–24 g, was determined 
prior to administration of BK-1361. The corresponding amount of peptide was then calculated and administered 
via i.p. 2 h prior to each aerosolized challenge every day for one week (please see Figure S1 in the supplements 
for detailed protocol). Mice in the control group were treated with the vehicle of peptide (PBS), using the same 
protocol.
Assessment of airway responsiveness. The lung function was assessed 24 h after the last allergen 
exposure by measuring the respiratory pressure curves in response to methacholine (MCh) stimulation using 
a single-chamber, whole-body plethysmography set-up (EMKA Technologies, Paris, France) as previously 
described52. Briefly, the animal was placed in a sealed single chamber and exposed to either aerosolized saline (for 
the baseline measurement) or MCh (with increasing concentrations ranging from 3.125–50 mg/mL) for 3 min 
each time. Then enhanced pause (Penh) was recorded for 3 min after each nebulization as an indicator of air-
way responsiveness. The value of Penh was calculated by Penh = PEP/PIP × Pause (where PEP, PIP and Pause 
represented the peak expiratory flow, the peak inspiratory flow and the time of expiration respectively), which 
was thought to be an unrestrained plethysmography parameter with high correlation to the airway resistance in 
Balb/c mouse strain49.
Assessment of bronchial inflammation. Mice were sacrificed 24 h after lung function testing, and bron-
choalveolar lavage fluid (BALF) was collected by inserting a cannula into the trachea of the mice with three 
instillations of 0.5 mL PBS. BALF was centrifuged at 239 g for 10 min at 4 °C. Supernatants were stored at −80 °C 
for further analysis whilst cell pellets were resuspended in PBS to proceed with total and differential cell counts. 
The total cell number was determined by direct microscopy. For the differential cell counts, cells suspended in 
~40–80 μL PBS was dropped upon a sterile slide, then a smear was made by streaking the cell suspension across 
the slide with a cover glass. The cells deposited on slides were then stained using the Wright–Giemsa method 
and subsequently counted by a skilled observer blinded to experimental details. The percentage of eosinophils, 
neutrophils, lymphocytes and macrophages were obtained respectively from each group at 400x magnification.
Assessment of bronchial tissue remodeling. After collection of BALF, the right lungs were harvested 
and snap frozen in liquid nitrogen for downstream RNA extraction and lung homogenates, whereas the left 
lung was insufflated at constant pressure with 4% buffered formaldehyde solution. Formalin-fixed lungs were 
processed and embedded in paraffin, cut to 5 μm sections, and stained with hematoxylin & eosin (H&E) and 
Picosirius-Red respectively. Histologic inflammatory scores were obtained by an experienced histologist blinded 
to experimental details under 200x magnification, who took into accounts of perivascular infiltration (PV), peri-
bronchial infiltration (PB), parenchymal infiltration (PA), and epithelial damage (ED) and gave an evaluation for 
each index. For each evaluation index, 0 point indicates no sign of disease whereas 5 point represents profound 
inflammation, thus the extent of the bronchial inflammation and associated tissue remodeling was presented as a 
total score point between 0 and 20 as described before2,11.
Quantification of mRNA expression of inflammatory cytokines in lung tissue. Total RNA of lung 
tissues were extracted using TRIzol and reverse transcribed using RevertAid First Strand cDNA Synthesis Kit. The 
sequences of oligonucleotide primers for IL-4, IL-5, IL-13, CCL5, CCL11 and CCL22, as shown in Table 2, were 
designed based on the nucleotide sequence available in NCBI Genbank. The specificity of selected sequences was 
verified using the NCBI BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/). The expression of mRNA for 
each gene was quantified using SsoFast EvaGreen Supermix, detection of β-actin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were chosen as endogenous controls. All reactions were run using the CFX96 real-time 
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PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Normalized fold expression of mRNA was 
calculated using Bio-Rad CFX Manager software 1.6 (Bio-Rad Laboratories, Hercules, CA, USA) based on the 
Pfaffl algorithm53.
Quantification of soluble CD23 and ADAM8 expressions in lung tissue lysates. Lung tissues from 
sensitized and challenged mice were homogenized in ice-cold PBS, and clarified by centrifugation (10000 rpm, 
10 min at 4 °C), then the supernatants were stored in liquid nitrogen for further analysis. Concentrations of the 
soluble CD23 (sCD23) and soluble ADAM8 (sADAM8) in the supernatants of lung extracts were measured using 
commercial ELISA kits according to the manufacturer’s instructions.
For analysis of BK-1361 in unchallenged mice, 4 wild-type (Adam8+/+) and 4 ADAM8-deficient (Adam8−/−) 
mice were injected i.p. with either 10 μg/g body weight of BK-1361 or with identical volumes of saline for one 
week. To test the CD23 in lysates, lung tissue was frozen in liquid nitrogen and grounded. The tissue powder was 
resuspended in 500 μL PBS containing 1%BSA and homogenized on ice for 45 s. To obtain the soluble protein 
fraction, the extract was centrifuged at 13.000 × g for 10 min at 4 °C. The soluble protein fraction was then used 
for ELISA analyses and protein concentrations were determined. CD23 ELISA assays were performed according 
to the manufacturer’s instructions and values were determined based on a standard curve. The lung tissue lysates 
were diluted 10 times for the test of total CD23, undiluted supernatants of lysates were used for the test of sCD23. 
The concentrations of sCD23 were normalized for protein concentrations (amount of BSA was subtracted from 
measured protein concentrations). All experiments were performed with pooled tissue from at least 3 mice and 
the values are derived from triplicate samples.
Immunohistochemistry (IHC) of mouse lungs. Lung sections (5 μm thickness) from paraffin-embedded 
lung tissues were deparaffinized in xylene and rehydrated by an alcohol gradient. Endogenous peroxidase activ-
ity was blocked with 3% hydrogen peroxide. Sections were incubated with citrate buffer for antigen retrieval 
and incubated with an antibody targeting ADAM8 (1:150) followed by the ABC Vectastain method using 
3,3′-diaminobenzidine (DAB) chromogen detection. Immunostained sections were counterstained with H&E 
and micrographs were taken using a Nikon Image Suite (Nikon, Tokyo, Japan).
Western blot. For analysis of BK-1361 in unchallenged mice, the lung tissues from either Adam8+/+ or 
Adam8−/− mice were powdered under liquid nitrogen and subjected to lysis using PBS containing 1% Triton-X100 
and 2x Complete Protease inhibitor cocktail (Roche, Germany) for 20 min on ice. 100 μg total protein per lane 
were subjected to a reducing 10% SDS-PAGE electrophoresis and Western blotting. Blots were blocked for 1 h 
with 5% milk powder in Tris buffered saline with 0.05% Tween (TBST), followed by 2 h incubation with 2 μg/mL 
polyclonal rabbit anti-CD23, which was detected with 27 ng/mL goat anti-rabbit HRP. After stripping, load-
ing was controlled by incubation with 25 ng/mL mouse anti-GAPDH in 5% milk powder and 27 ng/mL goat 
anti-mouse HRP in TBST. Quantification of bands was performed using AIDA Image Analyzer software (Raytest, 
Straubenhardt, Germany).
Sequence (5′-3′) Length (bp)a Accession No.b
IL-4 FW CAAACGTCCTCACAGCAACG
166 M25892, X05253, NM_021283RV AGGCATCGAAAAGCCCGAAA
IL-5 FW CCCTCATCCTCTTCGTTGCAT
72 X06270, X06271, NM_010558.1RV CCCTTGGCTACACACTGAGTT
IL-13 FW CCAGCCCTCAGCCATGAAATA
111 M23504, L13028, NM_008355RV CACCTTGAGTGTAACAGGCCA
CCL5 FW CAGCAGCAAGTGCTCCAATC
238 NM_013653
RV CCATTTTCCCAGGACCGAGT
CCL11 FW AACCCAGAGCCTAAGAACTGC
236 NM_011330
RV CTCGTCCCATTGTGTTCCTCA
CCL22 FW GCTCTCGTCCTTCTTGCTGT
208 NM_009137
RV GGATCGGCACAGATATCTCG
β-actin FW AGAGGGAAATCGTGCGTGAC
138 X03672, V01217, J00691, M_007393.3RV CAATAGTGATGACCTGGCCGT
GAPDH FW TCACCACCATGGAGAAGGC
168 M32599, U09964, NM_008084RV GCTAAGCAGTTGGTGGTGCA
Table 2.  Oligonucleotide primers used for RT-PCR. The first column lists the tested cytokines including 
interleukin (IL) 4, 5, 13; chemokine (C-C motif) ligand (CCL) 5, 11, 22; and references of β-actin and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The second column indicates either forward (FW) 
or reverse (RV) primer. The sequence of each primer, its length and accession number are listed in the 3rd–5th 
column. The superscript a, and b denotes amplicon length in base pairs, and Genbank accession number of 
mRNA and corresponding gene (http://www.ncbi.nlm.nih.gov/), respectively.
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Statistics. The ANOVA analysis of variance followed by Tukey’s honestly significant difference analysis 
(Tukey’s HSD) and Student t-test was applied for statistical analysis, the value of */#P < 0.05, **/##P < 0.005 were 
considered significant. Statistical analysis was performed with the OriginPro 8.5.1 SR2 (OriginLab Corporation, 
Northampton, MA, USA); Graphs were obtained using SigmaPlot 10.0 (Systat Software Inc., Chicago, IL, USA).
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